These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 25497280)
1. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. Montes de Oca R; Gurard-Levin ZA; Berger F; Rehman H; Martel E; Corpet A; de Koning L; Vassias I; Wilson LO; Meseure D; Reyal F; Savignoni A; Asselain B; Sastre-Garau X; Almouzni G Mol Oncol; 2015 Mar; 9(3):657-74. PubMed ID: 25497280 [TBL] [Abstract][Full Text] [Related]
2. The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Hu Z; Huang G; Sadanandam A; Gu S; Lenburg ME; Pai M; Bayani N; Blakely EA; Gray JW; Mao JH Breast Cancer Res; 2010; 12(2):R18. PubMed ID: 20211017 [TBL] [Abstract][Full Text] [Related]
3. Unraveling the Role of Histone Variant CENP-A and Chaperone HJURP Expression in Thymic Epithelial Neoplasms. Levidou G; Palamaris K; Sykaras AG; Andreadakis G; Masaoutis C; Theochari I; Korkolopoulou P; Rontogianni D; Theocharis S Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955489 [TBL] [Abstract][Full Text] [Related]
4. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. McGovern SL; Qi Y; Pusztai L; Symmans WF; Buchholz TA Breast Cancer Res; 2012 May; 14(3):R72. PubMed ID: 22559056 [TBL] [Abstract][Full Text] [Related]
5. HJURP is involved in the expansion of centromeric chromatin. Perpelescu M; Hori T; Toyoda A; Misu S; Monma N; Ikeo K; Obuse C; Fujiyama A; Fukagawa T Mol Biol Cell; 2015 Aug; 26(15):2742-54. PubMed ID: 26063729 [TBL] [Abstract][Full Text] [Related]
6. MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. Issac MSM; Yousef E; Tahir MR; Gaboury LA Neoplasia; 2019 Oct; 21(10):1015-1035. PubMed ID: 31476594 [TBL] [Abstract][Full Text] [Related]
7. Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Polo SE; Theocharis SE; Klijanienko J; Savignoni A; Asselain B; Vielh P; Almouzni G Cancer Res; 2004 Apr; 64(7):2371-81. PubMed ID: 15059888 [TBL] [Abstract][Full Text] [Related]
8. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. O'Brien SL; Fagan A; Fox EJ; Millikan RC; Culhane AC; Brennan DJ; McCann AH; Hegarty S; Moyna S; Duffy MJ; Higgins DG; Jirström K; Landberg G; Gallagher WM Int J Cancer; 2007 Apr; 120(7):1434-43. PubMed ID: 17205517 [TBL] [Abstract][Full Text] [Related]
9. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572 [TBL] [Abstract][Full Text] [Related]
10. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Holm K; Hegardt C; Gunnarsson H; Fagerholm R; Strand C; Agnarsson BA; Kilpivaara O; Luts L; Heikkilä P; Aittomäki K; Blomqvist C; Loman N; Malmström P; Olsson H; Johannsson OT; Arason A; Nevanlinna H; Barkardottir RB; Borg A Breast Cancer Res; 2010; 12(3):R42. PubMed ID: 20576095 [TBL] [Abstract][Full Text] [Related]
11. HJURP interaction with the condensin II complex during G1 promotes CENP-A deposition. Barnhart-Dailey MC; Trivedi P; Stukenberg PT; Foltz DR Mol Biol Cell; 2017 Jan; 28(1):54-64. PubMed ID: 27807043 [TBL] [Abstract][Full Text] [Related]
12. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Dunleavy EM; Roche D; Tagami H; Lacoste N; Ray-Gallet D; Nakamura Y; Daigo Y; Nakatani Y; Almouzni-Pettinotti G Cell; 2009 May; 137(3):485-97. PubMed ID: 19410545 [TBL] [Abstract][Full Text] [Related]
13. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups. Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of centromere recruitment of the CENP-A chaperone HJURP and its implications for centromere licensing. Pan D; Walstein K; Take A; Bier D; Kaiser N; Musacchio A Nat Commun; 2019 Sep; 10(1):4046. PubMed ID: 31492860 [TBL] [Abstract][Full Text] [Related]
15. Essential role for centromeric factors following p53 loss and oncogenic transformation. Filipescu D; Naughtin M; Podsypanina K; Lejour V; Wilson L; Gurard-Levin ZA; Orsi GA; Simeonova I; Toufektchan E; Attardi LD; Toledo F; Almouzni G Genes Dev; 2017 Mar; 31(5):463-480. PubMed ID: 28356341 [TBL] [Abstract][Full Text] [Related]
16. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Aure MR; Vitelli V; Jernström S; Kumar S; Krohn M; Due EU; Haukaas TH; Leivonen SK; Vollan HK; Lüders T; Rødland E; Vaske CJ; Zhao W; Møller EK; Nord S; Giskeødegård GF; Bathen TF; Caldas C; Tramm T; Alsner J; Overgaard J; Geisler J; Bukholm IR; Naume B; Schlichting E; Sauer T; Mills GB; Kåresen R; Mælandsmo GM; Lingjærde OC; Frigessi A; Kristensen VN; Børresen-Dale AL; Sahlberg KK; Breast Cancer Res; 2017 Mar; 19(1):44. PubMed ID: 28356166 [TBL] [Abstract][Full Text] [Related]
17. A Dual Inhibitory Mechanism Sufficient to Maintain Cell-Cycle-Restricted CENP-A Assembly. Stankovic A; Guo LY; Mata JF; Bodor DL; Cao XJ; Bailey AO; Shabanowitz J; Hunt DF; Garcia BA; Black BE; Jansen LET Mol Cell; 2017 Jan; 65(2):231-246. PubMed ID: 28017591 [TBL] [Abstract][Full Text] [Related]
18. Phosphorylation and DNA binding of HJURP determine its centromeric recruitment and function in CenH3(CENP-A) loading. Müller S; Montes de Oca R; Lacoste N; Dingli F; Loew D; Almouzni G Cell Rep; 2014 Jul; 8(1):190-203. PubMed ID: 25001279 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349 [TBL] [Abstract][Full Text] [Related]
20. A novel subtype classification and risk of breast cancer by histone modification profiling. Chen X; Hu H; He L; Yu X; Liu X; Zhong R; Shu M Breast Cancer Res Treat; 2016 Jun; 157(2):267-279. PubMed ID: 27178334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]